Worldwide Biotech/Biopharma Alliance (Dec. 20 – Dec. 19)
On Dec. 20, 2013, Novogen Limited announced the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
On Dec. 20, 2013, Takeda Pharmaceutical Company Limitedand Natrogen Therapeutics International, Inc. jointly announced an agreement whereby Takeda will acquire an exclusive license to develop Natrogen’s Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis (UC).
On Dec. 19, 2013, Sanofi and Regeneron Pharmaceuticals, Inc. announced an innovative collaboration with the American College of Cardiology (ACC) focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
On Dec. 19, 2013, AmorChem announce the financing of a project in neuro-inflammation in collaboration with Dr. Philippe Gros, Professor in the Department of Biochemistry and Vice-Dean, Life Sciences, of the Faculty of Medicine of McGill University. Using a sophisticated in vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, Dr. Gros recently discovered a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes.
Article Link: Worldwide Biotech/Biopharma Alliance (Dec. 20 – Dec. 19)Tags: Newsletter, Cancer, Monoclonal Antibody, DUB, Cytokine